Virulent Clones of Klebsiella Pneumoniae: Identification and Evolutionary Scenario Based on Genomic and Phenotypic Characterization
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
The Rcs Phosphorelay May Regulate the E. Coli Capsule Response to Sublethal Streptomycin Treatment
Journal of Experimental Microbiology and Immunology (JEMI) Copyright © April 2015, M&I UBC The Rcs Phosphorelay May Regulate the E. coli Capsule Response to Sublethal Streptomycin Treatment Iris Luo, Josh Wiebe, Yunan Liu Department of Microbiology and Immunology, University of British Columbia The Escherichia coli colanic acid capsule produced by the cps gene confers resistance in the presence of sublethal antibiotic concentrations. However, the exact mechanism of capsule gene regulation in reaction to the presence of antibiotics is unknown. The two main proposed cps regulation pathways both involve the Rcs phosphorelay system, but differ regarding dependence on RpoS for cps transcription. In this study, we explored the changes in capsule formation and antibiotic resistance in response to treatment with sublethal concentrations of streptomycin using deletion mutants of the two proposed regulation pathways. Wild type, Δ rcsB, Δ rpoS, and Δ cps. E. coli strains were incubated in sublethal concentrations of streptomycin. When examined with MIC assays, the deletion mutants showed higher levels of antibiotic resistance compared to wild type strains of E. coli. We also demonstrated that capsule production was induced under sublethal streptomycin conditions with Maneval staining. Furthermore, qPCR detection of cps transcription indicated downregulation in Δ rcsB strains and upregulation in Δ rpoS after streptomycin treatment. Together, these results suggest that E. coli streptomycin resistance is not dependent on capsule production, and that rcsB and rpoS may both play a role in cps regulation when treated with sublethal doses of streptomycin. Escherichia coli are rod shaped bacteria capable of producing a polysaccharide capsule. The capsule is important for protection from desiccation, survival during oxidative stress, bacterial virulence, and antibiotic resistance (1). -
(12) United States Patent (10) Patent No.: US 9,018,158 B2 Onsoyen Et Al
US0090181.58B2 (12) United States Patent (10) Patent No.: US 9,018,158 B2 Onsoyen et al. (45) Date of Patent: Apr. 28, 2015 (54) ALGINATE OLIGOMERS FOR USE IN 7,208,141 B2 * 4/2007 Montgomery .................. 424/45 OVERCOMING MULTIDRUG RESISTANCE 22:49 R: R388 al al W . aSOC ea. N BACTERA 7,671,102 B2 3/2010 Gaserod et al. 7,674,837 B2 3, 2010 G d et al. (75) Inventors: Edvar Onsoyen, Sandvika (NO); Rolf 7,758,856 B2 T/2010 it. Myrvold, Sandvika (NO); Arne Dessen, 7,776,839 B2 8/2010 Del Buono et al. Sandvika (NO); David Thomas, Cardiff 2006.8 R 38 8. Melist al. (GB); Timothy Rutland Walsh, Cardiff 2003/0022863 A1 1/2003 Stahlang et al. (GB) 2003/0224070 Al 12/2003 Sweazy et al. 2004/OO73964 A1 4/2004 Ellington et al. (73) Assignee: Algipharma AS, Sandvika (NO) 2004/0224922 A1 1 1/2004 King 2010.0068290 A1 3/2010 Ziegler et al. (*) Notice: Subject to any disclaimer, the term of this 2010/0305062 A1* 12/2010 Onsoyen et al. ................ 514/54 patent is extended or adjusted under 35 U.S.C. 154(b) by 184 days. FOREIGN PATENT DOCUMENTS DE 268865 A1 1, 1987 (21) Appl. No.: 13/376,164 EP O324720 A1 T, 1989 EP O 506,326 A2 9, 1992 (22) PCT Filed: Jun. 3, 2010 EP O590746 A1 4f1994 EP 1234584 A1 8, 2002 (86). PCT No.: PCT/GB2O1 O/OO1097 EP 1714660 A1 10, 2006 EP 1745705 A1 1, 2007 S371 (c)(1), FR T576 M 3/1968 (2), (4) Date: Jan. -
Klebsiella Ornithinolytica
international Journal of Systematic Bacteriology (1 999), 49, 1695-1 700 Printed in Great Britain Phylogenetic evidence for reclassification of Calymmatobacterium granulomatis as Klebsiella granulomatis comb. nov. Jenny 5. Carter,’l2 Francis J. B~wden,~Ivan Ba~tian,~Garry M. Myers,’ K. S. Sriprakash’ and David J. Kemp’ Author for correspondence : David J. Kemp. Tel : + 6 18 8922 84 12. Fax : + 6 18 8927 5 187 e-mail : [email protected] 1 Menzies School of Health By sequencing a total of 2089 bp of the 16s rRNA and phoE genes it was Research, Darwin, demonstratedthat Calymmatobacterium grandomatis (the causative Austra Iia organism of donovanosis) shows a high level of identity with Klebsiella * Centre for Indigenous species pathogenic to humans (Klebsiellapneumoniae, Klebsiella Natural and Cultural Resource Management, rhinoscleromatis). It is proposed that C. grandomatis should be reclassified as Faculty of Aboriginal and Klebsiella granulomatis comb. nov. An emended description of the genus Torres Strait Islander Klebsiella is given. Studies, Northern Territory University, Darwin, Australia 3 Institute of Medical and Keywords : Calymmatobacteriurn, Klebsiella, sequence data, phylogenetic inferences Veterinary Science, Adelaide, Australia 4 AIDS/STD Unit, Royal Darwin Hospital, Darwin, Australia Calymmatobacterium granulomatis is the presumed ganism (Richens, 1991) have prevented further char- causative agent of donovanosis, an important cause of acterization of this relationship. genital ulceration that occurs in small endemic foci in all continents except Europe and Antarctica. The name Non-cultivable pathogenic eubacteria have been C. granulomatis was originally given to the pleo- identified by PCR using primers targeting conserved morphic bacterium cultured from donovanosis lesions genes (Fredricks & Relman, 1996). -
Ohio Department of Health, Bureau of Infectious Diseases Disease Name Class A, Requires Immediate Phone Call to Local Health
Ohio Department of Health, Bureau of Infectious Diseases Reporting specifics for select diseases reportable by ELR Class A, requires immediate phone Susceptibilities specimen type Reportable test name (can change if Disease Name other specifics+ call to local health required* specifics~ state/federal case definition or department reporting requirements change) Culture independent diagnostic tests' (CIDT), like BioFire panel or BD MAX, E. histolytica Stain specimen = stool, bile results should be sent as E. histolytica DNA fluid, duodenal fluid, 260373001^DETECTED^SCT with E. histolytica Antigen Amebiasis (Entamoeba histolytica) No No tissue large intestine, disease/organism-specific DNA LOINC E. histolytica Antibody tissue small intestine codes OR a generic CIDT-LOINC code E. histolytica IgM with organism-specific DNA SNOMED E. histolytica IgG codes E. histolytica Total Antibody Ova and Parasite Anthrax Antibody Anthrax Antigen Anthrax EITB Acute Anthrax EITB Convalescent Anthrax Yes No Culture ELISA PCR Stain/microscopy Stain/spore ID Eastern Equine Encephalitis virus Antibody Eastern Equine Encephalitis virus IgG Antibody Eastern Equine Encephalitis virus IgM Arboviral neuroinvasive and non- Eastern Equine Encephalitis virus RNA neuroinvasive disease: Eastern equine California serogroup virus Antibody encephalitis virus disease; LaCrosse Equivocal results are accepted for all California serogroup virus IgG Antibody virus disease (other California arborviral diseases; California serogroup virus IgM Antibody specimen = blood, serum, serogroup -
Bacillus Subtilis
Das Phagenschock-Protein LiaH aus Bacillus subtilis Dissertation der Fakultät für Biologie der Ludwig-Maximilians-Universität München Vorgelegt von aus Leisnig München April 2012 1. Gutachter: Prof. Dr. Thorsten Mascher 2. Gutachterin: Prof. Dr. Ute Vothknecht Tag der Abgabe: 10.04.2012 Tag der mündlichen Prüfung: 31.10.2012 Eidesstattliche Versicherung und Erklärung Hiermit versichere ich an Eides statt, dass die vorliegende Dissertation von mir selbständig und ohne unerlaubte Hilfe angefertigt wurde. Zudem wurden keine anderen als die angegebenen Quellen verwendet. Außerdem versichere ich, dass die Dissertation keiner anderen Prüfungskommission vorgelegt wurde und ich mich nicht anderweitig einer Doktorprüfung ohne Erfolg unterzogen habe. München, den 10.04.2012 ____________________________ Diana Wolf „Nichts beflügelt die Wissenschaft so, wie der Schwatz mit Kollegen auf dem Flur.“ Arno Penzias (*1933), amerik. Physiker, 1978 Nobelpreis Inhaltsverzeichnis Inhaltsverzeichnis Publikationsliste IV Abkürzungsverzeichnis V Zusammenfassung VII Summary IX Kapitel I: Einleitung 1 I.1. Aufbau der bakteriellen Zellwand 1 I.2. Zellwandbiosynthese 2 I.3. Die Zellwand als Ziel von antibiotisch wirkenden Substanzen 5 I.4. Die Zellhüllstressantwort in Gram-positiven Bakterien am Beispiel B. subtilis 8 I.5. Das LiaFSR-Dreikomponentensystem in B. subtilis 11 I.5.1. Induktion des LiaFSR-3KS 12 I.5.2. Regulation und Funktion des LiaFSR-3KS 12 I.6. Die Zellhüllstressantwort in Gram-negativen Bakterien am Beispiel E. coli 14 I.7. Die Phagenschock-Antwort in E. coli 16 I.7.1. Induktion der Phagenschock-Antwort 17 I.7.2. Regulation der Phagenschock-Antwort 18 I.7.3. Rolle der Phagenschock-Antwort im Energiestoffwechsel 20 I.8. Die Phagenschock-Antwort in anderen Organismen 20 I.8.1. -
The Old Testament Is Dying a Diagnosis and Recommended Treatment 1St Edition Download Free
THE OLD TESTAMENT IS DYING A DIAGNOSIS AND RECOMMENDED TREATMENT 1ST EDITION DOWNLOAD FREE Brent A Strawn | 9780801048883 | | | | | David T. Lamb Strawn offers a few other concrete suggestions about how to save the Old Testament, illustrating several of these by looking at the book of Deuteronomy as a model for second language acquisition. Retrieved 27 August The United States' Centers for Disease Control and Prevention CDC currently recommend that individuals who have been diagnosed and treated for gonorrhea avoid sexual contact with others until at least one week past the final day of treatment in order to prevent the spread of the bacterium. Brent Strawn reminds us of the Old Testament's important role in Christian faith and practice, criticizes current misunderstandings that contribute to its neglect, and offers ways to revitalize its use in the church. None, burning with urinationvaginal dischargedischarge from the penispelvic paintesticular pain [1]. Stunted language learners either: leave faith behind altogether; remain Christian, but look to other resources for how to live their lives; or balkanize in communities that prefer to speak something akin to baby talk — a pidgin-like form of the Old Testament and Bible as a whole — or, worse still, some sort of creole. Geoff, thanks for the reference. Log in. The guest easily identified the passage The Old Testament Is Dying A Diagnosis and Recommended Treatment 1st edition the New Testament, but the Old Testament passage was a swing, and a miss. Instead, our system considers things like how recent a review is and if the reviewer bought the item on Amazon. -
Sexually Transmitted Diseases (Stds) 2016 Update Tirdad T
Sexually Transmitted Diseases (STDs) 2016 Update Tirdad T. Zangeneh, DO, FACP Associate Professor of Clinical Medicine Division of Infectious Diseases University of Arizona – Banner Medical Center Disclosures • I have no financial relationships to disclose. • I will not discuss off-label use and/or investigational use in my presentation. • Slides provided by various sources including AETC, CDC, DHHS, and Dr. Sharon Adler. Arizona STDs 2014: 39,919 cases of STDs reported in Arizona: • Maricopa (64.4%) • Pima (16.8%) • Pinal (4.1%) • Yuma (2.6%) – 1.2% of investigated cases were co-infected with HIV – 22.8% of investigated cases were men who have sex with men (MSM) – 79.5% of all reported cases were young adults 15 – 29 years of age Arizona STDs • Pima County – 55 cases of syphilis in 2013 – 142 cases of syphilis in 2014 • As a result of the year to year increase, the syphilis rate in Pima County increased by 158% (14.2 cases per 100,000 population in 2014) Clinical Prevention Guidance The prevention and control of STDs are based on the following 5 major strategies: • Accurate risk assessment, education, and counseling on ways to avoid STDs through changes in sexual behaviors and use of recommended prevention services • Pre-exposure vaccination of persons at risk for vaccine- preventable STDs (Human Papillomavirus and Hepatitis B Virus • Identification of asymptomatically infected persons and persons with symptoms associated with STDs Clinical Prevention Guidance The prevention and control of STDs are based on the following 5 major strategies: • Effective diagnosis, treatment, counseling, and follow up of infected persons • Evaluation, treatment, and counseling of sex partners of persons who are infected with an STD The Five P’s approach to obtaining a sexual history 1. -
Sexually Transmitted Infections
MASSACHUSETTS DEPARTMENT OF PUBLIC HEALTH GUIDE TO SURVEILLANCE, REPORTING AND CONTROL Sexually Transmitted Infections June 2013 | Page 1 of 6 Section 1 ABOUT THE INFECTIONS Gonorrhea A. Etiologic Agent Neisseria gonorrhoeae are bacteria that appear as gram-negative diplococci on microscopic Gram-stained smear. B. Clinical Description Many infections occur without symptoms. Most males with urethral infection have symptoms of purulent or mucopurulent urethral discharge. Men may also have epididymitis due to N. gonorrhoeae . Most infections in women are asymptomatic. Symptoms in women can include abdominal pain, and mucopurulent or purulent cervical discharge. Women may also get urethritis. N. gonorrhoeae can cause pelvic inflammatory disease. Disseminated (bloodstream) infection can occur with rash, and joint and tendon inflammation. Infections of the throat and the rectum can also occur and are often asymptomatic. C. Vectors and Reservoirs Humans are the only known natural hosts and reservoirs of infection. D. Modes of Transmission Gonorrhea is transmitted through oral, vaginal, or anal sex. Gonorrhea can also be transmitted at birth through contact with an infected birth canal. E. Incubation Period The incubation period for gonorrhea is usually 2-7 days for symptomatic disease. F. Period of Communicability or Infectious Period All sexual contacts within 60 days of the onset of symptoms or diagnosis of gonorrhea should be evaluated and treated. Individuals with asymptomatic infection are infectious as long as they remain infected. G. Epidemiology Gonorrhea is the second most commonly reported notifiable disease in the U.S.; over 300,000 cases are reported annually. The number of reported cases underestimates true incidence. H. Treatment Ceftriaxone 250 mg IM x 1 dose PLUS EITHER Azithromycin 1 gram PO x 1 dose (preferred) OR Doxycycline 100 mg PO twice daily for 7 days is the recommended treatment in Massachusetts. -
Table of Contents I. Introduction and Background:
2013 State Reportable Conditions Assessment (SRCA) User Instructions Table of Contents I. Introduction and Background: ................................................................................................................................... 1 II. Tips for completing the SRCA ..................................................................................................................................... 2 III. Getting Started ........................................................................................................................................................... 2 IV. Managing Users and Assigning Sections for Data Entry ............................................................................................ 3 V. Entering Data for Reportable Conditions ................................................................................................................... 4 VI. 2012 Data Interpolation ............................................................................................................................................. 9 VII. Review and Submit Completed Data ....................................................................................................................... 10 VIII. APPENDIX 1: Alphabetical List of Conditions by Condition Category Grouping (*Nationally Notifiable Conditions [NNC]) ............................................................................................................................................................................... 11 IX. APPENDIX -
Search Strategy
Appendix 1: Search Strategy. Search #1 "HIV Infections"[Mesh] OR "HIV" [MeSH] OR “human immunodeficiency virus”[tiab] OR “human immuno deficiency virus”[tiab] OR “human immune deficiency virus”[tiab] OR “human immunedeficiency virus”[tiab] OR “aids”[tiab] OR “acquired immunodeficiency syndrome”[tiab] OR “acquired immunodeficiency syndromes”[tiab] OR “acquired immuno deficiency syndrome”[tiab] OR “acquired immuno deficiency syndromes”[tiab] OR “acquired immune deficiency syndrome”[tiab] OR “acquired immune deficiency syndromes”[tiab] OR “acquired immunedeficiency syndrome”[tiab] OR “acquired immunedeficiency syndromes”[tiab] Search #2 "mHealth" [tiab] OR "telemedicine"[MeSH] OR telemedicine[tiab] OR eHealth[MeSH] OR ehealth[tiab] OR "mobile health" [tiab] OR “mobile technology”[tiab] OR “app”[tiab] OR “apps”[tiab] OR “mobile applications” OR social medi*[tiab] OR cell phone* [tiab] OR cellphone*[tiab] OR “cellular phone”[mesh] OR cellular phone*[tiab] OR smartphone*[tiab] OR smart phone*[tiab] OR mobile phone[tiab] OR mobile device*[tiab] OR cellular telephone*[tiab] OR mobile telephone*[tiab] OR text messag*[tiab] OR texting[tiab] OR texted[tiab] OR SMS[tiab] OR MMS[tiab] OR multimedia messag*[tiab] OR short messag*[tiab] OR “computers, handheld”[mesh] OR personal digital assistant*[tiab] Search #3 [1,2] sexually transmitted infections[mh] OR sexually transmitted disease*[tiab] OR sexually transmissible disease*[tiab] OR sexually transmitted infection*[tiab] OR sexually transmissible infection*[tiab] OR sexually transmitted infectious disease*[tiab] OR sexually References transmissible infectious disease*[tiab] OR sexually transmitted disorder*[tiab] OR sexually transmissible disorder*[tiab] OR STI[tiab] OR 1.Ferreira A, Young T, Mathews C, Zunza M, STIs[tiab] OR STD[tiab] OR STIs[tiab] OR venereal disease*[tiab] OR venereal infection*[tiab] OR venereal disorder*[tiab] OR genital Low N. -
Laboratory Diagnosis of Sexually Transmitted Infections, Including Human Immunodeficiency Virus
Laboratory diagnosis of sexually transmitted infections, including human immunodeficiency virus human immunodeficiency including Laboratory transmitted infections, diagnosis of sexually Laboratory diagnosis of sexually transmitted infections, including human immunodeficiency virus Editor-in-Chief Magnus Unemo Editors Ronald Ballard, Catherine Ison, David Lewis, Francis Ndowa, Rosanna Peeling For more information, please contact: Department of Reproductive Health and Research World Health Organization Avenue Appia 20, CH-1211 Geneva 27, Switzerland ISBN 978 92 4 150584 0 Fax: +41 22 791 4171 E-mail: [email protected] www.who.int/reproductivehealth 7892419 505840 WHO_STI-HIV_lab_manual_cover_final_spread_revised.indd 1 02/07/2013 14:45 Laboratory diagnosis of sexually transmitted infections, including human immunodeficiency virus Editor-in-Chief Magnus Unemo Editors Ronald Ballard Catherine Ison David Lewis Francis Ndowa Rosanna Peeling WHO Library Cataloguing-in-Publication Data Laboratory diagnosis of sexually transmitted infections, including human immunodeficiency virus / edited by Magnus Unemo … [et al]. 1.Sexually transmitted diseases – diagnosis. 2.HIV infections – diagnosis. 3.Diagnostic techniques and procedures. 4.Laboratories. I.Unemo, Magnus. II.Ballard, Ronald. III.Ison, Catherine. IV.Lewis, David. V.Ndowa, Francis. VI.Peeling, Rosanna. VII.World Health Organization. ISBN 978 92 4 150584 0 (NLM classification: WC 503.1) © World Health Organization 2013 All rights reserved. Publications of the World Health Organization are available on the WHO web site (www.who.int) or can be purchased from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; e-mail: [email protected]). Requests for permission to reproduce or translate WHO publications – whether for sale or for non-commercial distribution – should be addressed to WHO Press through the WHO web site (www.who.int/about/licensing/copyright_form/en/index.html). -
The Reduction of T7 Phage Adsorption in Escherichia Coli B23 Cells Treated with Sub-Lethal Levels of Kanamycin
Journal of Experimental Microbiology and Immunology (JEMI) Vol. 13:89-92 Copyright © April 2009, M&I UBC The Reduction of T7 Phage Adsorption in Escherichia coli B23 Cells Treated with Sub-Lethal Levels of Kanamycin Joanne Bleackley, Jesse Cooper, Monica Kaminski and Stephanie Sandilands Department of Microbiology & Immunology, UBC The production of capsular material has been implicated as a bacterial defence mechanism against certain antibiotics and against phage adsorption. The capsule acts to block the phage from binding to its receptor on the bacterial cell which effectively inhibits phage adsorption. Previously, it has been shown that exposing Escherichia coli B23 cells to sub-inhibitory levels of the antibiotic kanamycin results in an increase in extracellular polysaccharide production, possibly in the form of a capsule. In the current study, this phenomenon was investigated using T7 phage adsorption as a model to assess the presence of a capsule. Phage adsorption assays were performed on both E. coli B23 cells treated with sub-lethal levels of kanamycin for 1 hour and untreated cells. T7 phage adsorption was shown to be diminished in E. coli treated with antibiotic, as compared to those which had not been treated with antibiotic. This decrease in phage adsorption to the antibiotic treated cells suggests that the induced extracellular polysaccharide produced by these cells is part of the capsule. Thus, this work provides further insight into the likely nature of the induced-extracellular polysaccharide produced by these cells following antibiotic treatment. Bacteria have developed mechanisms to adapt to phage adsorption (17). Binding of T7 phage to LPS changes in their environment.